SBMFF (Sino Biopharmaceutical) Beneish M-Score: -2.87 (As of Jun. 25, 2026)


SBMFF Sino Biopharmaceutical Ltd SBMFF
62 GF Score
Price $0.60
GF Value $0.68
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Sino Biopharmaceutical Beneish M-Score?

Sino Biopharmaceutical SBMFF -4.96% 62 Beneish M-Score is -2.87 as of Jun. 25, 2026. GuruFocus rates SBMFF with a GF Score™ of 62/100 and a GF Value™ of $0.68 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 831 Biotechnology companies, Sino Biopharmaceutical ranks better than 70.16% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.87 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Sino Biopharmaceutical's Beneish M-Score or its related term are showing as below:

SBMFF' s Beneish M-Score Range Over the Past 10 Years
Min: -3.39   Med: -2.75   Max: -0.35
Current: -2.87

During the past 13 years, the highest Beneish M-Score of Sino Biopharmaceutical was -0.35. The lowest was -3.39. And the median was -2.75.


Sino Biopharmaceutical Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Sino Biopharmaceutical's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sino Biopharmaceutical Beneish M-Score Chart

Sino Biopharmaceutical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.11 -2.77 -2.73 -2.62 -2.87

Sino Biopharmaceutical Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.73 0.00 -2.62 0.00 -2.87

SBMFF vs VRTX, REGN, ALNY: Beneish M-Score Comparison

For the Biotechnology subindustry, Sino Biopharmaceutical's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sino Biopharmaceutical Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Sino Biopharmaceutical's Beneish M-Score falls into.


SBMFF
62GF Score
Sino Biopharmaceutical Ltd SBMFF
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sino Biopharmaceutical Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Sino Biopharmaceutical for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0493+0.528 * 0.9932+0.404 * 0.8853+0.892 * 1.14+0.115 * 1.075
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9796+4.679 * -0.091415-0.327 * 1.3065
=-2.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was $1,117 Mil.
Revenue was $4,520 Mil.
Gross Profit was $3,710 Mil.
Total Current Assets was $4,893 Mil.
Total Assets was $10,792 Mil.
Property, Plant and Equipment(Net PPE) was $1,453 Mil.
Depreciation, Depletion and Amortization(DDA) was $172 Mil.
Selling, General, & Admin. Expense(SGA) was $1,865 Mil.
Total Current Liabilities was $3,578 Mil.
Long-Term Debt & Capital Lease Obligation was $1,086 Mil.
Net Income was $333 Mil.
Gross Profit was $0 Mil.
Cash Flow from Operations was $1,319 Mil.
Total Receivables was $934 Mil.
Revenue was $3,965 Mil.
Gross Profit was $3,232 Mil.
Total Current Assets was $3,391 Mil.
Total Assets was $8,984 Mil.
Property, Plant and Equipment(Net PPE) was $1,413 Mil.
Depreciation, Depletion and Amortization(DDA) was $181 Mil.
Selling, General, & Admin. Expense(SGA) was $1,670 Mil.
Total Current Liabilities was $2,686 Mil.
Long-Term Debt & Capital Lease Obligation was $286 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1117.283 / 4519.89) / (933.991 / 3964.751)
=0.247193 / 0.235574
=1.0493

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(3231.824 / 3964.751) / (3709.5 / 4519.89)
=0.815139 / 0.820706
=0.9932

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (4893.383 + 1452.948) / 10791.944) / (1 - (3390.516 + 1413.072) / 8983.761)
=0.411938 / 0.465303
=0.8853

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=4519.89 / 3964.751
=1.14

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(181.463 / (181.463 + 1413.072)) / (172.022 / (172.022 + 1452.948))
=0.113803 / 0.105862
=1.075

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(1865.176 / 4519.89) / (1670.097 / 3964.751)
=0.41266 / 0.421236
=0.9796

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((1086.337 + 3577.858) / 10791.944) / ((285.707 + 2686.073) / 8983.761)
=0.432192 / 0.330795
=1.3065

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(332.711 - 0 - 1319.261) / 10791.944
=-0.091415

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Sino Biopharmaceutical has a M-score of -2.88 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.87 mean?
Sino Biopharmaceutical (SBMFF) has a Beneish M-Score of -2.87 as of Jun. 25, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Sino Biopharmaceutical and its competitors. According to the industry distribution chart, Sino Biopharmaceutical ranks #248 out of 831 companies in the Biotechnology industry, placing it in the top 29.8%.
Is Sino Biopharmaceutical's Beneish M-Score too high?
Sino Biopharmaceutical's current Beneish M-Score is -2.87. Based on the distribution chart, Sino Biopharmaceutical ranks #248 out of 831 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Sino Biopharmaceutical has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sino Biopharmaceutical's Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sino Biopharmaceutical ranks #248 out of 831 companies for Beneish M-Score. This puts Sino Biopharmaceutical in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Sino Biopharmaceutical and its competitors. Sino Biopharmaceutical's current Beneish M-Score is -2.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sino Biopharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Sino Biopharmaceutical (SBMFF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.68, compared to a current price of $0.60 — trading 11.5% below its estimated fair value. The current Beneish M-Score is -2.87. Sino Biopharmaceutical's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Sino Biopharmaceutical (SBMFF), the current Beneish M-Score is -2.87 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sino Biopharmaceutical (SBMFF) Overvalued in 2026?

Based on GuruFocus' analysis, Sino Biopharmaceutical stock appears to be undervalued. The current stock price of $0.60 is trading 11.5% below its estimated GF Value™ of $0.68. GuruFocus considers Sino Biopharmaceutical to be Modestly Undervalued.

Key valuation signals for SBMFF:

  • Beneish M-Score: -2.87
  • GF Value™: $0.68 vs. price of $0.60 (11.5% below fair value)
  • GF Score™: 62/100 with 4 warning signs

No single metric tells the full story. See the SBMFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sino Biopharmaceutical Business Description

Address 1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG
Sino Biopharmaceutical Ltd is an investment holding company. The company and its subsidiaries are principally engaged in the research and development, production and sale of a series of pharmaceutical products. Its business covering the entire industrial chain of R&D, production and commercialization of drugs, biological products and high-end generic drugs. The company's therapeutic areas include: oncology, liver disease, respiratory, and surgery/pain relief. The company's revenue was generated from the sale of pharmaceutical products in the Chinese mainland.
62GF Score

Get the complete analysis for SBMFF

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.60
Price
$0.68
GF Value